Evaluation of perceived threat differences posed by filovirus variants.
about
Animal models for Ebola and Marburg virus infectionsThe Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivoA systematic screen of FDA-approved drugs for inhibitors of biological threat agentsGenomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreakMammalian biogeography and the Ebola virus in AfricaEmerging targets and novel approaches to Ebola virus prophylaxis and treatmentDelayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaquesStandardization of the filovirus plaque assay for use in preclinical studiesMouse models for filovirus infectionsThe etiology of Ebola virus disease-like illnesses in Ebola virusnegative patients from Sierra LeoneEpigraph: A Vaccine Design Tool Applied to an HIV Therapeutic Vaccine and a Pan-Filovirus VaccineBIRS - Bioterrorism Information Retrieval System.Ebola virus genome plasticity as a marker of its passaging history: a comparison of in vitro passaging to non-human primate infection.Clinical illness and outcomes in patients with Ebola in Sierra Leone.Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccineMolecular Characterization of the First Ebola Virus Isolated in Italy, from a Health Care Worker Repatriated from Sierra LeoneInforming the Historical Record of Experimental Nonhuman Primate Infections with Ebola Virus: Genomic Characterization of USAMRIID Ebola Virus/H.sapiens-tc/COD/1995/Kikwit-9510621 Challenge Stock "R4368" and Its Replacement "R4415".High-resolution Crystal Structure of Dimeric VP40 From Sudan ebolavirus.Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques.Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.Forty-five years of Marburg virus research.Virus nomenclature below the species level: a standardized nomenclature for natural variants of viruses assigned to the family Filoviridae.Modeling the lifecycle of Ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes.Ebola virus does not block apoptotic signaling pathways.A web-based resource for designing therapeutics against Ebola VirusVirus-Like Particle Vaccination Protects Nonhuman Primates from Lethal Aerosol Exposure with Marburgvirus (VLP Vaccination Protects Macaques against Aerosol Challenges).Correspondence of Neutralizing Humoral Immunity and CD4 T Cell Responses in Long Recovered Sudan Virus SurvivorsHost cell factors in filovirus entry: novel players, new insightsClinical presentation and management of severe Ebola virus disease.Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection.Animal models for ebolavirus countermeasures discovery: what defines a useful model?Validation of the Filovirus Plaque Assay for Use in Preclinical StudiesSudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRIProfile and persistence of the virus-specific neutralizing humoral immune response in human survivors of Sudan ebolavirus (Gulu).Ebola: where did it come from and where might it go?Rapid detection and quantification of Ebola Zaire virus by one-step real-time quantitative reverse transcription-polymerase chain reaction.Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys.An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.Vaccines against 'the other' Ebolavirus species.Ebola virus disease: from epidemiology to prophylaxis.
P2860
Q21131118-473C2E8E-67E6-48BF-965D-CDFADD72A9F0Q21131393-573C3136-C0D6-4333-9A4C-75E3457D8ADDQ21559667-831D303F-8AFF-48A6-B1A4-E8F65311F520Q23000449-CE94F5D8-AF0C-4174-A590-744A6563CB00Q24578541-D4F0E44F-6F98-404B-ACE2-9E5E90C3295FQ24597625-6AFC08EC-0EBC-4B15-AC07-A7BC33391A4BQ24612811-0A3F8A81-7023-4DFA-96D4-2E3D4C0E0600Q27000207-5419750E-B3F9-416E-95F3-37FE110D3535Q27011569-5214B100-E4CE-4188-ADA0-3A5A2186CE2CQ28391090-77C9853F-3D1F-4812-BDA3-2913EBF2CF84Q28822525-992D2D09-C246-4696-9DE0-43B617DEE0D9Q30223390-2C7E77E7-4257-41C1-B561-54971B5B143CQ34500139-167532DA-87D1-46C4-80D1-4F0665D601FEQ35053891-9B75E055-38D0-4B82-AE80-3180D2275490Q35184639-82946DEF-B2FE-422B-9D29-7E356050437BQ35756962-4B42E496-8B61-445B-8CA3-0952E35EAEA5Q35965936-FA1007B5-F1A4-46F2-A161-0EA0FA2C4DD8Q36043187-17B9FC47-AA74-415E-B297-FB6B61F50A2EQ36080908-79E911A5-AA7B-48C7-A969-0905E5471E5DQ36210186-5349FEFE-7EA7-41AA-A19B-9044EEFECCC6Q36395831-9E462C80-4BCD-4736-AB7D-6F2CE22DA02FQ36504020-6ADCE94F-46F8-456F-A50B-43DCD20BE1F4Q36788332-02731A66-4752-44DC-855D-9EB2DCA07C77Q36827365-FAF0ED31-ED7D-476F-BBE1-25DFC0863991Q36835666-8B530FF2-413D-4619-AC6A-CB951EDAA3EAQ36845999-FA6A98E3-AC7D-46AC-B627-2CE33DB496FAQ36947021-5EE619F4-9801-4503-8972-1F5C89220014Q38076136-DA378534-F139-4BE3-8C76-446D7BBD1E1AQ38264960-13A35690-0B9A-42BA-A870-D1F2602AC2D6Q38478474-944803DA-D666-43A5-9B6F-F331FDE897E7Q38500788-47E32DB2-6330-45EB-B111-0EE7319B38C5Q38775636-7FB304FC-A88D-4C2B-AFC6-D48C936F0552Q38848145-7F42BE41-777C-46CE-B29B-F28D6CA9A4F4Q38848208-2F52CFC5-DC65-4142-AC39-74D15FEC8505Q38917409-54EDFE93-C496-41DA-8FC3-01FA8070838EQ40064193-79792B7F-0779-421B-A1DA-F129B82DBE6FQ40067156-B153C35D-EDEA-4F7A-BB21-9B5C4A4441FDQ40095257-035C3BCA-935F-47D0-9EED-C285353CD55DQ40112699-3DF05BF5-34D4-4B32-BA00-0654C23F5693Q40154928-B63C0D26-783E-45D4-9E5A-4FF8F36EFAC3
P2860
Evaluation of perceived threat differences posed by filovirus variants.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Evaluation of perceived threat differences posed by filovirus variants.
@ast
Evaluation of perceived threat differences posed by filovirus variants.
@en
type
label
Evaluation of perceived threat differences posed by filovirus variants.
@ast
Evaluation of perceived threat differences posed by filovirus variants.
@en
prefLabel
Evaluation of perceived threat differences posed by filovirus variants.
@ast
Evaluation of perceived threat differences posed by filovirus variants.
@en
P2860
P50
P356
P1476
Evaluation of perceived threat differences posed by filovirus variants.
@en
P2093
Lori E Dodd
P2860
P304
P356
10.1089/BSP.2011.0051
P577
2011-11-09T00:00:00Z